Lake Street lowered the firm’s price target on OS Therapies (OSTX) to $13 from $14 and keeps a Buy rating on the shares following the company’s Q1 update. 2.5-year overall survival data will be released at ASCO in just a couple of weeks, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
- OS Therapies Delays Quarterly SEC Filing
- OS Therapies Gains EMA Rolling Review for OST-HER2
- OSTX Earnings this Week: How Will it Perform?
- OS Therapies bolsters funding to advance OST-HER2 program
- Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program